Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience Lynette M. Sholl, MD, Dara.

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas Rong Fang, PhD, Chao Zheng, PhD, Yihua.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Neal I. Lindeman,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor Sai F. Yeung, BSc, Joanna H.M. Tong,

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Geoffrey R. Oxnard, MD, Vincent A. Miller, MD, Mark E

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis Sinéad A. Noonan,

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Erratum Journal of Thoracic Oncology

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains Chenguang Li, MD,

Laurie A. Hohberger, MD, Darrell R. Schroeder, MS, Brian J

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

A Translational View of the Molecular Pathogenesis of Lung Cancer

Clinical Characteristics, Tumor, Node, Metastasis Status, and Mutation Rate in Domain of Epidermal Growth Factor Receptor Gene in Serbian Patients with.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Anne S. Tsao, MD, Suyu Liu, PhD, J. Jack Lee, PhD, Christine M

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Goulnar Kasymjanova, MD, José A

Phase I Study of Lenalidomide in Solid Tumors

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Ernest Nadal, MD, Guoan Chen, MD, PhD, John R

Genetic Changes in Squamous Cell Lung Cancer: A Review

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

IASLC 6th Latin American Conference on Lung Cancer

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Robert Comis, MD, The Passing of a “Lung Man”

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience Lynette M. Sholl, MD, Dara L. Aisner, MD, PhD, Marileila Varella-Garcia, PhD, Lynne D. Berry, PhD, Dora Dias-Santagata, PhD, Ignacio I. Wistuba, MD, Heidi Chen, PhD, Junya Fujimoto, MD, PhD, Kelly Kugler, BA, Wilbur A. Franklin, MD, A. John Iafrate, MD, PhD, Marc Ladanyi, MD, Mark G. Kris, MD, Bruce E. Johnson, MD, Paul A. Bunn, MD, John D. Minna, MD, David J. Kwiatkowski, MD, PhD Journal of Thoracic Oncology Volume 10, Issue 5, Pages 768-777 (May 2015) DOI: 10.1097/JTO.0000000000000516 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Mutations identified in the LCMC cohort. A pie chart is shown in which the size of each slice is proportional to the mutation frequency in the full genotyping set of 733 patients. Cases with two mutations are represented only once based on the mutation that primarily dictated clinical care in each patient. As a result, the frequencies of ALK, MET, and PIK3CA alterations appear lower in this figure. (See Table 2 for details.) Frequencies presented here also differ slightly for some genes in comparison with frequencies for the any-genotyping group (n = 1007). See details of the full-genotyping versus any-genotyping cohorts and a comprehensive breakdown of all mutations identified in our original article on the LCMC experience, Ref. 14. Journal of Thoracic Oncology 2015 10, 768-777DOI: (10.1097/JTO.0000000000000516) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Demographic and prognostic associations with any and individual specific mutations. Statistically significant and other notable associations are shown in the form of bar graphs for several mutation types. “Any” refers to any identified mutation. KRAS, EGFR, and ERBB2 consist of all point mutations occurring in those genes; ALK refers to translocations involving ALK, and MET refers to amplification of the MET locus, identified by FISH. More detailed demographic and prognostic association data are provided in Supplemental Table 7 (Supplemental Digital Content 1, http://links.lww.com/JTO/A814). Journal of Thoracic Oncology 2015 10, 768-777DOI: (10.1097/JTO.0000000000000516) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions